Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18

10/2/2026
Impact: 75
Healthcare

Truist Securities analyst Srikripa Devarakonda has maintained a Buy rating on Inventiva (NASDAQ: IVA) and raised the price target from $13 to $18. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: